Identification
- Generic Name
- Magnesium Aluminum Silicate
- DrugBank Accession Number
- DB11230
- Background
-
Magnesium aluminum silicate is a naturally occurring mineral obtained from silicate ores of the montmorillonite group1。这是重新fined to a powder for use in cosmetic and pharmaceutical applications as an absorbent, anticaking agent, opacifying agent, viscosity-increasing agent, suspending agent, tablet and capsule disintegrant, and tablet binder. It also has antacid properties and is used as a component of some over the counter antacid medications.
- Type
- Small Molecule
- Groups
- Approved
- Synonyms
-
- Aluminii magnesii silicas
- Aluminium magnesium silicate
- Aluminium magnesium silicate hydrate
- Aluminium magnesium silicate polyhydrate
- Aluminum magnesium silicate
- Magnesium aluminium silicate
- Magnesium aluminium silicate hydrate
- Magnesium aluminum silicate hydrate
- External IDs
-
- M-907015
- MJ-2000
Pharmacology
- Indication
-
Magnesium aluminum silicate is used as an over the counter antacid for the self-treatment of heartburn, sour stomach, or acid indigestionLabel。
Reduce drug development failure ratesBuild, train, & validate machine-learning models
with evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets. - Contraindications & Blackbox Warnings
-
Avoid life-threatening adverse drug eventsImprove clinical decision support with information oncontraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.
- Pharmacodynamics
-
Magnesium aluminum silicate neutralizes excess acid in the stomach to reduce or eliminate symptoms of heartburn, sour stomach, or acid indigestionLabel
- Mechanism of action
-
Magnesium aluminum silicate reacts with acid in the stomach to increase the pH.
- Absorption
-
Not Available
- Volume of distribution
-
Not Available
- Protein binding
-
Not Available
- Metabolism
- Not Available
- Route of elimination
-
Not Available
- Half-life
-
Not Available
- Clearance
-
Not Available
- Adverse Effects
-
Improve decision support & research outcomesWith structured adverse effects data, including:blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
-
The LD50 in mice is considered to be >50000 mg/kg with oral suspensions of magnesium aluminum silicate1。真皮LD50被认为是ob > 3.5克/公斤served in rabbits. Magnesium aluminum silicate produced mild skin irritation. In a 90 day study in rats, animal fed a diet with 20% magnesium aluminum silicate had slightly stunted growth. With 5% and 10% the rats had increased silicone content in the spleen. At 2% one male rat died and at 10% one male and female rat died. These rats had fibrous exudates in the thorax and hemorrhage in the lungs with evidence of infection. No evidence of teratogenicity or mutagenicity was found in the appropriate studies.
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRsBrowse all" title="" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug InteractionsLearn More" title="" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
-
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your software阿曲库 The therapeutic efficacy of Atracurium can be increased when used in combination with Magnesium Aluminum Silicate. 阿曲库besylate The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Magnesium Aluminum Silicate. Botulinum toxin type A The therapeutic efficacy of Botulinum toxin type A can be increased when used in combination with Magnesium Aluminum Silicate. Botulinum toxin type B The risk or severity of adverse effects can be increased when Magnesium Aluminum Silicate is combined with Botulinum toxin type B. Capreomycin The risk or severity of neuromuscular blockade can be increased when Capreomycin is combined with Magnesium Aluminum Silicate. Chloroquine The risk or severity of neuromuscular blockade can be increased when Chloroquine is combined with Magnesium Aluminum Silicate. Cisatracurium The therapeutic efficacy of Cisatracurium can be increased when used in combination with Magnesium Aluminum Silicate. Clindamycin The risk or severity of neuromuscular blockade can be increased when Clindamycin is combined with Magnesium Aluminum Silicate. Colistimethate The risk or severity of neuromuscular blockade can be increased when Colistimethate is combined with Magnesium Aluminum Silicate. Colistin The risk or severity of neuromuscular blockade can be increased when Colistin is combined with Magnesium Aluminum Silicate. Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Products
-
Drug product information from 10+ global regionsOur datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions. - International/Other Brands
- Veegum
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 6M3P64V0NC
- CAS number
- 1327-43-1
References
- General References
-
- Elmore AR: Final report on the safety assessment of aluminum silicate, calcium silicate, magnesium aluminum silicate, magnesium silicate, magnesium trisilicate, sodium magnesium silicate, zirconium silicate, attapulgite, bentonite, Fuller's earth, hectorite, kaolin, lithium magnesium silicate, lithium magnesium sodium silicate, montmorillonite, pyrophyllite, and zeolite. Int J Toxicol. 2003;22 Suppl 1:37-102. [Article]
- External Links
- FDA label
-
Download (306 KB)
- MSDS
-
Download (47 KB)
Clinical Trials
- Clinical TrialsLearn More" title="" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
-
Phase Status Purpose Conditions Count
Pharmacoeconomics
- Manufacturers
-
Not Available
- Packagers
-
Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
-
Property Value Source water solubility Insoluble MSDS - Predicted Properties
- Not Available
- Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
Drug created at December 03, 2015 16:51 / Updated at January 07, 2021 03:13